Table 3.
1° CHLa | 2° CHL | ||
---|---|---|---|
Groupb | Ricin | LT | Ricin |
RiVax A | - | 0/5 | - |
B | 5/5* | - | - |
DNI A | - | 5/5* | 0/5 |
B | 0/4c | - | - |
Dual A | - | 4/5 | 4/4* |
B | 5/5 | - | - |
Vehicle A | - | 0/5 | - |
B | 0/5 | - | - |
CHL, challenge;
Each group of mice (left column) was arbitrarily divided into two subsets, A and B. The A subset received a primary challenge with LT, while the B subset (shaded) received a primary challenge with ricin. The DNI-immunized and the dual-immunized A subsets of animals that survived LT challenge received a secondary challenge with ricin;
A single mouse in this group of animals died of unknown causes prior to the animal’s second immunization.
, indicates statistical significance (p<0.05) based on the Mantel-Cox test.